Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 426 participants.

Also called NCT02769481

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 426 participants (enrolled count) (from the registry)
Sponsor
  • Theracos Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02769481
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany, Poland, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02769481. Randomized; quadruple masking; primary purpose treatment. Start 2016-08-15 (actual); primary completion 2019-06-14 (actual). Results posted on 2021-05-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Bexagliflozin
Intervention (Drug)
Placebo for Bexagliflozin
Intervention (Drug)
Glimepiride
Intervention (Drug)
Placebo for Glimepiride
Lead sponsor
Theracos (class: industry)

Record details

Record id
cardio:ct-nct02769481
Content hash
2e9043194f4d63c2478050a7c2bcb2459c1b1761a6846ac1ba5e2979938ca5eb